scholarly journals A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro

Surgery ◽  
2021 ◽  
Vol 169 (1) ◽  
pp. 34-42
Author(s):  
Chitra Subramanian ◽  
Rebecca Gorney ◽  
Ton Wang ◽  
Derek Ge ◽  
Nina Zhang ◽  
...  
2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Jun Zhou ◽  
Li-Li He ◽  
Xiao-Fei Ding ◽  
Qiu-Qi Yuan ◽  
Jian-Xin Zhang ◽  
...  

Background.mTOR signaling would be a promising target for thyroid cancer therapy. However, in clinical trials, objective response rate with mTOR inhibitor monotherapy in most cancer types was modest. A new focus on development of combinatorial strategies with rapalogs is increasing.Objective.Investigating the combinatorial antitumor effect of rapamycin andβ-elemene in follicular thyroid cancer cells.Methods.MTT assay was used to determine the FTC-133 cell proliferation after culturing with rapamycin and/orβ-elemene. To analyze their combinatorial effect, immunoblotting was performed to analyze the activation status of AKT. Moreover,β-elemene attenuated rapamycin-induced immunosuppression was tested in mice.Results.Combination of rapamycin andβ-elemene exerted significant synergistic antiproliferative effects in FTC-133 cell linesin vitro, based on inhibiting the AKT feedback activation induced by rapamycin.In vivo, theβ-elemene could attenuate rapamycin-induced immunosuppression via reversing imbalance of Treg/Th17, with the underlying mechanism needed to be declared.Conclusions. We demonstrate that the novel combination of mTOR inhibitor withβ-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation.


Endocrine ◽  
2006 ◽  
Vol 30 (1) ◽  
pp. 129-138 ◽  
Author(s):  
S. Hoffmann ◽  
K. Maschuw ◽  
I. Hassan ◽  
A. Wunderlich ◽  
S. Lingelbach ◽  
...  

Surgery ◽  
2020 ◽  
Vol 167 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Timothy M. Ullmann ◽  
Heng Liang ◽  
Maureen D. Moore ◽  
Isra Al-Jamed ◽  
Katherine D. Gray ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Yaoyue Qi ◽  
Weiwei Qi ◽  
Shihai Liu ◽  
Libin Sun ◽  
Aiping Ding ◽  
...  

Abstract Background The issue of drug resistance in gastric cancer has attracted global attention. TSPAN9, a 4-transmembrane protein that plays an important role in tumor progression and signal transduction, has been found to be closely related to tumor invasion, metastasis, and autophagy. Methods Immunoblotting was used to evaluate TSPAN9 expression in parental and drug-resistant gastric cancer cells. Functional assays, such as the CCK-8 assay, were used to detect the proliferation of gastric cancer cells and the response of TSPAN9 to 5-fluorouracil (5-FU). Western blotting was used to analyze the expression of constituents of the PI3K/AKT/mTOR-mediated autophagy pathway induced by TSPAN9. Coimmunoprecipitation was performed to assess the specific mechanism by which TSPAN9 affects the PI3K pathway. Results We demonstrated that TSPAN9 is overexpressed in 5-FU-resistant cells compared to parental cells. 5-FU-mediated inhibition of cell proliferation can be significantly restored by increasing TSPAN9 expression, and inhibiting this expression in drug-resistant cells can restore the sensitivity of the cells to 5-FU. In addition, TSPAN9 also significantly promoted autophagy in gastric cancer cells in vitro. Further studies indicated that TSPAN9 downregulates the expression of PI3K and proteins associated with PI3K-mediated autophagy. In addition, TSPAN9 interacts with PI3K and inhibits its catalytic activity. Conclusion The current study reveals the important role of TSPAN9 in drug resistance to 5-FU in gastric cancer. It also provides a new target to clinically address drug-resistant gastric cancer and will contribute to the treatment strategy of this disease.


2017 ◽  
Vol 64 (11) ◽  
pp. 1115-1123 ◽  
Author(s):  
Aya Sawa ◽  
Tomohiro Chiba ◽  
Jun Ishii ◽  
Hiroyuki Yamamoto ◽  
Hisato Hara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document